Correction: Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: The HPV FOCAL randomized clinical trial (JAMA - Journal of the American Medical Association (2018) 320:1 (43-52) DOI: 10.1001/jama.2018.7464);Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: The HPV FOCAL randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 320, Issue 1, 2018, Pages 43-52

  Ogilvie, Gina Suzanne ^a,b   Van Niekerk, Dirk ^c,d   Krajden, Mel ^a,b   Smith, Laurie W ^d   Cook, Darrel ^b,d   Gondara, Lovedeep ^d   Ceballos, Kathy ^d   Quinlan, David ^a   Lee, Marette ^d   Martin, Ruth Elwood ^a   Gentile, Laura ^d   Peacock, Stuart ^e,f,g   Stuart, Gavin C E ^a   Franco, Eduardo L ^h   Coldman, Andrew J ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c Lower Mainland Pathology and Laboratory Medicine   (Canada)

^d Cervical Cancer Screening Program   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f Canadian Centre for Applied Research in Cancer Control   (Canada)

^g SIMON FRASER UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANADA; CANCER SCREENING; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; LIQUID BASED CYTOLOGY; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; CANCER GRADING; CLINICAL TRIAL; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROCEDURES; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM GRADING; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 85049721732     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.17912     Document Type: Erratum

References (26)

1. Arbyn M, Rebolj M, De Kok IM, et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer. 2009;45(15):2671-2678. doi:10.1016/j.ejca.2009.07.016
2. American Society of Clinical Oncology. Cervical cancer: statistics. Cancer.net. http://www.cancer.net/cancer-types/cervical-cancer/statistics. Published July 2017. Accessed April 14, 2018.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1):12-19. doi:10.1002/(SICI)1096-9896(199909) 189:1<12::AID-PATH431>3.0.CO;2-F
4. Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016; 63(4):519-527. doi:10.1093/cid/ciw354
5. Jeronimo J, Castle PE, Temin S, et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Glob Oncol. 2016;3(5):635-657. doi:10.1200/JGO .2016.006577
6. Murphy J, Kennedy EB, Dunn S, et al. HPV testing in primary cervical screening: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2012;34(5):443-452. doi:10.1016 /S1701-2163(16)35241-0
7. Ronco G, Dillner J, Elfström KM, et al; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532. doi:10.1016/S0140-6736 (13)62218-7
8. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178-182. doi:10.1016/j .ygyno.2014.12.022
9. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force: Evidence Syntheses, No. 86s. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
10. Moyer VA; US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2013;158(11):852]. Ann Intern Med. 2012;156(12):880-891, W312. doi:10.7326/0003 -4819-156-12-201206190-00424
11. Coldman AJ, Gondara L, Smith LW, et al. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. Br J Cancer. 2016;115(12):1487-1494. doi:10.1038/bjc.2016.368
12. Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111. doi:10.1186/1471-2407-10-111
13. Ogilvie GS, Krajden M, van Niekerk DJ, et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial: the HPV FOCAL Study. Br J Cancer. 2012;107(12):1917-1924. doi:10.1038/bjc.2012.489
14. Ogilvie GS, Krajden M, van Niekerk D, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017;140(2):440-448. doi:10.1002/ijc.30454
15. Wilson E. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209-212. doi:10.1080/01621459.1927 .10502953
16. R Core Team. R: A Language and Environment for Statistical Computing. 2016. http://www.R-project.org/.
17. Tota JE, Bentley J, Blake J, et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Prev Med. 2017; 98:5-14. doi:10.1016/j.ypmed.2016.11.029
18. Mayrand MH, Duarte-Franco E, Rodrigues I, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579-1588. doi:10.1056 /NEJMoa071430
19. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249-257. doi:10.1016/S1470-2045(09)70360-2
20. Louvanto K, Chevarie-Davis M, Ramanakumar AV, Franco EL, Ferenczy A. HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol. 2014;210(5): 474.e1-474.e7. doi:10.1016/j.ajog.2013.12.033
21. Dillner J, Rebolj M, Birembaut P, et al; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754. doi:10.1136 /bmj.a1754
22. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18-25. doi:10.1097/AOG .0b013e31818f5008
23. Agramunt S, Checa MA, González-Comadrán M, et al. High-grade squamous intraepithelial lesion could be managed conservatively in women up to 25 years: results from a retrospective cohort study. J Low Genit Tract Dis. 2013;17(4):459-462. doi:10.1097/LGT.0b013e3182838b7c
24. Loopik DL, Doucette S, Bekkers RL, Bentley JR. Regression and progression predictors of CIN2 in women younger than 25 years. J Low Genit Tract Dis. 2016;20(3):213-217. doi:10.1097/LGT .0000000000000215
25. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370 (9601):1764-1772. doi:10.1016/S0140-6736(07) 61450-0
26. Dijkstra MG, van Zummeren M, Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ. 2016;355:i4924. doi:10.1136/bmj.i4924